JP2022545005A5 - - Google Patents
Info
- Publication number
- JP2022545005A5 JP2022545005A5 JP2022511096A JP2022511096A JP2022545005A5 JP 2022545005 A5 JP2022545005 A5 JP 2022545005A5 JP 2022511096 A JP2022511096 A JP 2022511096A JP 2022511096 A JP2022511096 A JP 2022511096A JP 2022545005 A5 JP2022545005 A5 JP 2022545005A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cancer
- egfr
- kras
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962890119P | 2019-08-22 | 2019-08-22 | |
| US62/890,119 | 2019-08-22 | ||
| PCT/US2020/047090 WO2021034992A1 (en) | 2019-08-22 | 2020-08-20 | Method of treating kras-associated cancers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022545005A JP2022545005A (ja) | 2022-10-24 |
| JP2022545005A5 true JP2022545005A5 (enExample) | 2023-08-28 |
| JP7602272B2 JP7602272B2 (ja) | 2024-12-18 |
Family
ID=74660044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022511096A Active JP7602272B2 (ja) | 2019-08-22 | 2020-08-20 | Ｋｒａｓ関連がんを治療する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220273643A1 (enExample) |
| EP (1) | EP4017489B1 (enExample) |
| JP (1) | JP7602272B2 (enExample) |
| KR (1) | KR20220050143A (enExample) |
| CN (2) | CN119454706A (enExample) |
| AU (1) | AU2020334069B2 (enExample) |
| BR (1) | BR112022003165A2 (enExample) |
| CA (1) | CA3150759A1 (enExample) |
| IL (1) | IL290454B2 (enExample) |
| MX (1) | MX2022002108A (enExample) |
| WO (1) | WO2021034992A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| AU2019338207B2 (en) | 2018-09-10 | 2025-01-02 | Mirati Therapeutics, Inc. | Combination therapies |
| CA3112043A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| US12208099B2 (en) | 2018-09-10 | 2025-01-28 | Mirati Therapeutics, Inc. | Combination therapies |
| SMT202500028T1 (it) | 2018-09-10 | 2025-03-12 | Mirati Therapeutics Inc | Terapie combinate |
| US12377101B2 (en) | 2018-12-05 | 2025-08-05 | Mirati Therapeutics, Inc. | Combination therapies |
| WO2020146613A1 (en) | 2019-01-10 | 2020-07-16 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| CN114615981B (zh) | 2019-08-29 | 2024-04-12 | 米拉蒂治疗股份有限公司 | Kras g12d抑制剂 |
| CN114761012B (zh) | 2019-09-24 | 2025-03-21 | 米拉蒂治疗股份有限公司 | 组合疗法 |
| PH12022551513A1 (en) | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| US12655160B2 (en) | 2020-08-04 | 2026-06-16 | Mirati Therapeutics, Inc. | KRAS G12D inhibitors |
| EP4210833A4 (en) | 2020-09-11 | 2024-09-11 | Mirati Therapeutics, Inc. | CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR |
| EP4216951B1 (en) | 2020-09-22 | 2026-04-01 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| EP4262807A4 (en) | 2020-12-15 | 2025-04-23 | Mirati Therapeutics, Inc. | Azachinazoline pan-KRAS inhibitors |
| WO2022133038A1 (en) | 2020-12-16 | 2022-06-23 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| KR20240016250A (ko) * | 2021-04-02 | 2024-02-06 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 암 치료를 위한 병용요법 |
| WO2023003417A1 (ko) * | 2021-07-22 | 2023-01-26 | 국립암센터 | Kras 돌연변이 특이적 저해제 및 이를 포함하는 암 예방 또는 치료용 조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| SI1913157T2 (sl) * | 2005-06-28 | 2017-02-28 | Genentech, Inc. | EGFR in KRAS mutacije za napoved bolnikovega odziva na zdravljenje z EGFR inhibitorjem |
| WO2010114922A1 (en) * | 2009-03-31 | 2010-10-07 | Agios Pharmaceuticals, Inc. | Methods of treating cancer having an aberrant egfr or kras genotype |
| JP2013542960A (ja) | 2010-11-08 | 2013-11-28 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド | 脂肪酸シンターゼ阻害剤 |
| US20140256767A1 (en) | 2011-10-31 | 2014-09-11 | The Broad Institute, Inc. | Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators |
| WO2014176475A2 (en) * | 2013-04-26 | 2014-10-30 | The Regents Of The University Of Michigan | Egfr inhibitors and uses thereof |
| AU2019223168B2 (en) * | 2018-02-23 | 2024-09-12 | The Regents Of The University Of Michigan | EGFR dimer disruptors and use of the same |
-
2020
- 2020-08-20 CN CN202411400491.9A patent/CN119454706A/zh active Pending
- 2020-08-20 BR BR112022003165A patent/BR112022003165A2/pt unknown
- 2020-08-20 CA CA3150759A patent/CA3150759A1/en active Pending
- 2020-08-20 EP EP20854314.0A patent/EP4017489B1/en active Active
- 2020-08-20 US US17/634,265 patent/US20220273643A1/en not_active Abandoned
- 2020-08-20 KR KR1020227007201A patent/KR20220050143A/ko active Pending
- 2020-08-20 WO PCT/US2020/047090 patent/WO2021034992A1/en not_active Ceased
- 2020-08-20 JP JP2022511096A patent/JP7602272B2/ja active Active
- 2020-08-20 MX MX2022002108A patent/MX2022002108A/es unknown
- 2020-08-20 AU AU2020334069A patent/AU2020334069B2/en active Active
- 2020-08-20 IL IL290454A patent/IL290454B2/en unknown
- 2020-08-20 CN CN202080059528.XA patent/CN114286676A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024507938A5 (enExample) | ||
| JP2024133474A5 (enExample) | ||
| JP2024023189A5 (enExample) | ||
| PH12023550130A1 (en) | Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of using same | |
| JP2024133475A5 (enExample) | ||
| JP2021526132A5 (enExample) | ||
| JP2021526133A5 (enExample) | ||
| CN102497864B (zh) | 用于预防或治疗由化疗诱发的疼痛的σ配体 | |
| JP5911929B2 (ja) | 特定の癌の治療のためのｒｄｅａ１１９／ｂａｙ８６９７６６を含む組み合わせ医薬 | |
| KR20140098799A (ko) | 암의 병용 치료 | |
| CN119454706A (zh) | 治疗kras相关癌症的方法 | |
| JP2015536986A5 (enExample) | ||
| JP2013507415A5 (enExample) | ||
| ES2877712T3 (es) | Terapias combinadas para su uso en el tratamiento del cáncer de mama | |
| JP2024520630A5 (enExample) | ||
| JP2023532675A5 (enExample) | ||
| KR20180100614A (ko) | 식도암을 치료하기 위한 퀴놀린 유도체의 용도 및 치료방법, 이의 약제학적 조성물 및 키트 | |
| KR102904026B1 (ko) | 헤테로시클릭 단백질 키나제 억제제를 포함하는 제제 | |
| JP2022535406A (ja) | Ｐｒｍｔ５阻害剤を使用した癌の治療法 | |
| JP2023011549A5 (enExample) | ||
| WO2004081012A1 (ja) | 抗腫瘍効果増強剤及び抗腫瘍剤 | |
| AU2015317856A1 (en) | Veliparib in combination with carboplatin and paclitaxel for the treatment of non-small cell lung cancer in smokers | |
| CN1575168A (zh) | 包含选择性环加氧酶－2抑制剂的组合 | |
| JP2021503448A5 (enExample) | ||
| JP2021091608A5 (enExample) |